Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients

The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.

DNA will be isolated from blood samples or paraffin-embedded tumor specimens and than a mutation analysis and SNPs genotyping will be done.

Inclusion Criteria:

• Availability of tumor tissue or blood samples.
• Diagnosis of NSCLC
• At least one treatment with EGFR-TKIs inhibitors

Exclusion Criteria:

• Other than NSCLC primary diagnosis
• No treatment with EGFR-TKIs inhibitors
• No archival tissue available